Welcome to our dedicated page for Caredx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading CareDx’s biotech-heavy disclosures often feels like decoding genomic sequences. Revenue tied to AlloSure testing, shifts in Medicare reimbursement, and R&D outlays for precision transplant diagnostics are scattered across multiple forms. Stock Titan delivers CareDx SEC filings explained simply, turning a 300-page document into a clear roadmap of growth drivers. Start with the CareDx annual report 10-K simplified to grasp long-term strategy, risk factors, and segment data without wading through dense technical jargon.
Need fast, decisive updates? Each CareDx quarterly earnings report 10-Q filing lands here within seconds of EDGAR release, accompanied by AI-powered summaries that highlight dd-cfDNA test volumes, gross margin trends, and pipeline investment. Real-time alerts surface CareDx Form 4 insider transactions real-time, so you can track when leadership buys or sells shares. Our AI also unpacks every CareDx 8-K material events explained, from new CMS coverage decisions to licensing agreements, ensuring no material development slips past you.
The result is a single destination that answers investors’ toughest questions: How are Medicare billing codes shaping cash flow? What do CareDx executive stock transactions Form 4 signal ahead of trial read-outs? Where is the board setting pay in the CareDx proxy statement executive compensation? With understanding CareDx SEC documents with AI, you receive concise risk commentary, comparable tables, and forward-looking indicators. Whether performing a CareDx earnings report filing analysis or scanning CareDx insider trading Form 4 transactions, our expert annotations and real-time feed provide the clarity and speed required to act confidently.
CareDx director Hannah Valantine has reported a significant insider transaction, selling 10,570 shares of common stock on June 18, 2025 at a weighted average price of $19.16 per share (ranging from $19.00 to $19.62). The total transaction value amounts to approximately $202,521.
The sale was executed under a Rule 10b5-1 trading plan established on December 12, 2024, which provides a pre-planned structure for insider trades. Following the transaction, Valantine retains direct ownership of 38,994 shares of CareDx common stock.
This transaction demonstrates a planned reduction in the director's holdings while maintaining a significant equity position in the company. The Rule 10b5-1 plan framework helps ensure compliance with insider trading regulations by establishing the trade parameters in advance.
CareDx Director Peter Maag has reported the sale of 10,000 shares of common stock at a weighted average price of $19.242 per share on June 17, 2025. The transaction was executed pursuant to a Rule 10b5-1 trading plan established on August 21, 2024.
The shares were sold in multiple transactions with prices ranging from $18.80 to $19.52. Following the reported transaction, Maag continues to hold 318,846 shares directly.
- Transaction Type: Sale (S)
- Ownership Type: Direct (D)
- Total Transaction Value: Approximately $192,420
- Trading Plan: Executed under pre-established 10b5-1 plan
This insider sale represents approximately 3% of Maag's direct holdings in CareDx and was conducted under a predetermined trading plan, which helps avoid concerns about insider trading.
CareDx, Inc. (CDNA) – Form 144 filing discloses a proposed sale of 10,570 common shares through Morgan Stanley Smith Barney on the NASDAQ. The shares, acquired as restricted stock units on 14 Jun 2025, carry an aggregate market value of $206,326.40, implying an indicative price of roughly $19.53 per share. The transaction is slated to occur on or about 18 Jun 2025. According to the filing, no other sales were made in the past three months, and the sale represents only ~0.02 % of the 55.68 million shares outstanding, suggesting minimal dilution or market impact. The filer certifies awareness of no undisclosed material adverse information and may be relying on a Rule 10b5-1 trading plan. Relationship to the issuer and filer identity were not provided in the excerpt.
FAQ
What is the current stock price of Caredx (CDNA)?
What is the market cap of Caredx (CDNA)?
What is the primary focus of CareDx Inc?
How does CareDx improve transplant patient care?
What types of transplant patients benefit from CareDx's testing services?
How does CareDx ensure the accuracy of its tests?
What differentiates CareDx from traditional diagnostic methods?
How does CareDx integrate its diagnostic solutions into broader patient care?
What role do clinical trials play in CareDx’s operations?
How does CareDx collaborate with other companies in the healthcare sector?
